Advertisement

Researchers at the Broad Institute in Cambridge and their collaborators, funded by the Multiple Myeloma Research Foundation, have sequenced the first multiple myeloma genome, a discovery they said could help drug developers better understand the disease and create new targets to treat it.

“The significance of the study is this is the first time the entire genome in multiple myeloma has been sequenced,” Kenneth Anderson, chief of the division of hematologic neoplasia at Boston’s Dana-Farber Cancer Institute, told Mass High Tech. “These studies allow us to better understand the genes that cause or are important in multiple myeloma. The clinical significance is to better segment patients and identify targets for potential novel treatments.” The research was published in this week’s issue of Nature magazine.

SOURCE

Advertisement
Advertisement